The National Medical Products Administration (NMPA) approved an investigational new drug (IND) application for WIN378 to ...

Using data from this trial, Laura Walrave, PhD, MS, BPharm, global medical director of CRSwNP at GSK, and colleagues evaluated 407 patients with at least one previous sinus surgery for CRSwNP to ...

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of WIN378 in patients with asthma, with a first data readout expected in mid-2026WIN378 has the potential to be the first-to-market ...

The monoclonal antibody against thymic stromal lymphopoietin (TSLP) improved total nasal-polyp score by a mean -2.07 points (95% CI −2.39 to −1.74) more than placebo on a 0-4 point scale at 52 ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

Chinese investigators recently studied the role of serum squamous cell carcinoma antigen (SCCA) and cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1) in the diagnosis of sinonasal diseases among ...